Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E 21 versus JUNEL FE 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E 21 versus JUNEL FE 1 5 30.
ENOVID-E 21 vs JUNEL FE 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone is a progestin that suppresses gonadotropin release, inhibiting ovulation; mestranol is an estrogen that stabilizes endometrium and provides cycle control.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
One tablet (norethynodrel 2.5 mg, mestranol 0.1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication. Repeat cycle.
One tablet orally once daily, each tablet containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets).
None Documented
None Documented
Terminal elimination half-life: 27–36 hours (mean 30.8 h). Steady-state reached after 5–7 days. Clinical context: allows once-daily dosing with stable estrogenic effect.
Norethindrone: 6-12 hours (terminal, multidose); ethinyl estradiol: 12-18 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; missed doses may reduce contraceptive efficacy.
73% renal (45% as unchanged norethindrone, 20% as conjugates, 8% as other metabolites), 27% fecal via bile. Enterohepatic recirculation accounts for 15% of total clearance.
Renal: 30-50% (norethindrone metabolites), 20-40% (ethinyl estradiol metabolites); biliary/fecal: 20-30% (norethindrone), 30-50% (ethinyl estradiol). Conjugated metabolites excreted in bile and undergo enterohepatic recirculation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive